Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.
The Tuskegee syphilis study stands as one of the greatest moral failures in American medical history, a reminder of what ...
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.
This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature https://doi.org/10.1038/s41586-025-09809-y (2025).
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback